Implants as drug delivery devices for the treatment of eye diseases

Brazilian Journal of Pharmaceutical Sciences

Volumn 46, Issue 3, 2010, Pages 585-595

  da Silva, Rodrigues ^a   Fialho, Sílvia Ligório ^b   Siqueira, Rubens Camargo ^c   Jorge, Rodrigo ^d   da Silva Cunha Júnior, Armando ^e  

^a FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

^b FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

^c Rubens Siqueira Ophthalmic Research Center

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Drugs delivery systems; Drugs prolonged delivery systems; Implants biodegradation; Pharmaceutical technology

Indexed keywords

ALTEPLASE; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; BETAMETHASONE; CILIARY NEUROTROPHIC FACTOR; CYCLOSPORIN A; DEXAMETHASONE; EYE DROPS; FLUOCINOLONE ACETONIDE; FLUOROURACIL; GANCICLOVIR; HYDROXYPROLINE; IMMUNOSUPPRESSIVE AGENT; POLY(METHYL METHACRYLATE); POLY(ORTHO ESTER); POLYCAPROLACTONE; POLYGLACTIN; RETINOIC ACID; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; CATARACT; CATARACT EXTRACTION; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CYTOMEGALOVIRUS RETINITIS; DEVICE REMOVAL; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG IMPLANT; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ENDOPHTHALMITIS; EPIRETINAL MEMBRANE; EYE DISEASE; HUMAN; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; IRVINE GASS SYNDROME; MEDICAL DEVICE; NON BIODEGRADABLE IMPLANT; NONHUMAN; POSTOPERATIVE PERIOD; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; SIDE EFFECT; TREATMENT DURATION; UVEITIS; VISUAL DISORDER; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

EID: 78650983532     PISSN: 19848250     EISSN: 21759790     Source Type: Journal    
DOI: 10.1590/s1984-82502010000300024     Document Type: Article

References (47)

1. AMO, E.M.; URTTI, A. Current and future ophthalmic drug delivery systems: A shift to the posterior segment. Drug Discov. Today, v.13, p.135-143, 2008.
2. ASHTON, P.; BROWN, J.D., PEARSON, P.A., BLANDFORD, D.L., SMITH, T.J., ANAND, R., NIGHTINGALE, S.D., SANBORN, G.E. Intravitreal ganciclovir pharmacokinetics in rabbits and man. J. Ocul. Pharmacol., v.8, p.343-347, 1992.
3. ÁVILA, M.A. Retina no Século XXI. Arq. Bras. Oftalmol., v.66, p.719-730, 2003.
4. BOURGES, J.L.; BLOQUEL, C.; THOMAS, A.; FROUSSART, F.; BOCHOT, A.; AZAN, F.; GURNY, R.; BENEZRA, D.; BEHAR-COHEN, F. Intra-ocular implants for extended drug delivery: Therapeutic applications. Adv. Drug Deliv. Rev., v.58, p.1182-1202, 2006.
5. CHANDRA, R.; RUSTGI, R. Biodegradable polymers. Prog. Polym. Sci., v.23, p.1273-1235, 1998.
6. CHARLES, N.C.; STEINER, G.C. Ganciclovir intra-ocular implant. A clinicopathologic study. Ophthalmolog., v.103, p.416-421, 1996.
7. CHENG, C-K.; BERGER, A.S.; PEARSON, P.A.; ASHTON, P.; JAFFE, G.J. Intravitreal sustained-release dexamethasone device in the treatment of experimental Uveitis. Invest. Ophthalmol. Vis. Sci., v.36, p.442-453, 1995.
8. DASH, A.K.; Cudworth, G.C. Therapeutic application of implantable drug delivery systems. J. Pharmacol. Toxicol. Methods, v.10, p.1-12, 1998.
9. DEBRA, A.G.; DAVID, G.G.; ANTHONY, H.; DAVID, G.C.; GLENN, J.J.; PEARSON, P.A.; DALE, W.U.; TIMOTHY, L.C. Intra-ocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch. Ophthalmol., v.125, p.1478-1485, 2007.
10. DONG, X.; CHEN, N.; XIE, L.; WANG, S. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal drug deliver system of all-trans retinoic acid. Retina, v.26, p.210-213, 2006.
11. EINMAHL, S.; BEHAN-COHEN, F.; TABATABAY, C.; D'HERMIES, F.; HELLER, J.; GURNY, R. A viscous bioerodible poly(ortho ester) as a new biomaterial for intra-ocular application. J. Biomed. Mater. Res., v.50, p.566-573, 2000.
12. EINMAHL, S.; PONSART, S.; BEJJANI, R.A.; DHERMIES, F.; SAVOLDELLI, M.; HELLER, J.; TABATABAY, C.; GURNY, R.; BEHAN-COHEN, F. Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation. J. Biomed. Mater. Res., v.67, p.44-53, 2003.
13. EINMAHL, S.; SAVOLDELLI, M.; DHERMIES, F.; TABATABAY, C.; GURNY, R.; BEHAN-COHEN, F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest. Ophthalmol. Vis. Sci., v.43, p.1533-1539, 2002.
14. FIALHO, S.L.; REGO, M.G.B.; CARDILLO, J.A.; SIQUEIRA, R.C.; JORGE, R.; SILVA-CUNHA, A. Implantes biodegradáveis destinados à administração intra-ocular. Arq. Bras. Oftalmol., v.66, p.891-896, 2003.
15. FIALHO, S.L.; SILVA-CUNHA, A. Manufacturing techniques of biodegradable implants intended to intraocular application. Drug Deliv., v.12, p.109-116, 2005.
16. FIALHO, S.L.; JORGE, R.; SIQUEIRA, R.C.; SILVA-CUNHA, A. Biodegradable implants for ocular delivery of anti-inflammatory drugs. J. Drug Del. Sci. Technol., v.17, p.93-97, 2007.
17. FIALHO, S.L.; BEHAR-COHEN, F.; SILVA-CUNHA, A. Dexamethasone-loaded poly(e-caprolactone) intravitreal implants: A pilot study. Eur. J. Pharm. Biopharm., v.68, p.637-646, 2008.
18. FIALHO, S.L.; REGO, M.G.B.; SIQUEIRA, R.C.; JORGE, R.; HADDAD, A.; RODRIGUES-JUNIOR, A.L.; MAIA-FILHO, A.; SILVA-CUNHA, A. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr. Eye. Res., v.31, p.525-534, 2006.
19. HERRER-OVANRELL, R.; REFOJO, M.F. Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev., v.52, p.5-16, 2001.
20. JAFFE, G.J.; MARTIN, D.; CALLANAN, D.; PEARSON, P.A.; LEVY, B.; COMSTOCK, T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology, v.113, p.1020-1027, 2006.
21. JAFFE, G.J.; YANG, C-S.; WANG, X-C.; COUSINS, S.W.; GALLEMORE, R.P.; ASHTON, P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology., v.105, p.46-56, 1998.
22. JAIN, R. A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, v.21, p.2475-2490, 2000.
23. KANE, F.E.; BURDAN, J.; CUTINO, A.; GREEN, K.E. Iluvien: a new sustained delivery technology for posterior eye diseases. Expert. Opin. Drug Deliv., v.5, p.1039-1046, 2008
24. KAPEL, P.J.; CHARONIS, A.C.; HOLLAND, G.N.; NARAYANAN, R.; KULKARNI, A.D.; YU, F.; BOYER, D.S.; ENGSTROM, R.E.; KUPPERMANN, B.D. Outcomes associated with ganciclovir implants in patients with SIDA-related cytomegalovirus retinitis. Ophthalmology, v.113, p.673-683, 2006.
25. KIM, Y.M.; LIM, J.O.; KIM, H.K.; KIM, S.L.; SHIN, J.P. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide. Eur. J. Pharm. Biopharm., v.70, p.179-186, 2008.
26. KIMURA, H.; OGURA, Y. Biodegradable polymers for ocular drugs delivery. Ophthalmologica., v.215, p.143-155, 2001.
27. KUNOU, N.; OGURA, Y.; HASHIZOE, M.; HONDA, Y.; HYON, S.; IKADA, Y. Controlled intra-ocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J. Control. Release., v.37, p.143-150, 1995.
28. KUNOU, N.; OGURA, Y.; YASUKAWA, T.; KIMURA, H.; MIYAMOTO, H.; HONDA, Y.; IKADA, Y. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J. Control. Release., v.68, p.263-271, 2000.
29. KUPPERMANN, B.D.; BLUMENKRANZ, M.S.; HALLER, J.A.; WILLIAMS, G.A.; WEINBERG, D.V.; CHOU, C.; WHITCUP, S.M. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol., v.25, p.309-317, 2007.
30. MACDONALD, I.M.; SAUVÉ, Y.; SIEVING, P.A. Preventing blindness in retinal disease: ciliary neurotrophic factor intra-ocular implants. Can. J. Ophthalmol., v.42, p.399-402, 2007.
31. MARTIN, D.F.; PARKS, D.J.; MELLOW, S.D.; FERRIS, F.L.; WALTON, R.C.; REMALEY, N.A.; CHEW, E.Y.; ASHTON, P.; DAVIS, M.D.; NUSSENBLATT, R.B. Treatment of cytomegalovirus retinitis with an intra-ocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch. Ophthalmol., v.112, p.1531-1539, 1994.
32. MOTTA, M.M.S.; COBLENTZ, J.; MELO, L.G.N. Aspectos atuais na fisiopatologia do edema macular diabético. Rev. Bras. Oftalmol., v.7, p.45-49, 2008.
33. NAIR, L.S.; LAURENCIN, C.T. Biodegradable polymers as biomaterials. Prog. Polym. Sci., v.32, p.762-798, 2007.
34. OKABE, J.; KIMURA, H.; KUNOU, N.; OKABE, K.; KATO, A.; OGURA, Y. Biodegradable intrascleral implant for sustained intra-ocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci., v.44, p.740-744, 2003.
35. PEYMAN, G.A.; GANIBAN, G.J. Delivery systems for intra-ocular routes. Adv. Drug Deliv. Rev., v.16, p.107-123, 2006.
36. RUBSAMEN, P.E.; DAVIS, P.A.; HERNANDEZ, E.; OGRADY, G.E.; COUSINS, S.W. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol., v.112, p.407-413, 1994.
37. SANBORN, G.E.; ANAND, R.; TORTI, R.E.; NIGHTINGALE, S.D.; CAL, S.X.; YATES, B.; ASHTON, P.; SMITH, T. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol., v.110, p.188-195, 1992.
38. SEAH, S.K.L.; HUSAIN, R.; GAZZARD, G.; LIM, M.C.C.; HOH, S-T.; OEN, F.T.S.; AUNG, T. Use of Surodex in phacotrabeculectomy surgery. Am. J. Ophthalmol., v.139, p.927-928, 2005.
39. SILVA-CUNHA, A.; FIALHO, S.L.; NAUD, M-C.; BEHAR-COHEN, F. Poly-e-caprolactone intravitreous devices: An in vivo study. Invest. Ophthalmol. Vis. Sci., v.50, p.2312-2318, 2009.
40. SIQUEIRA, R.C.; RIBEIRO, E.F.; FIALHO, S.L.; LUCENA, L.R.; MAIA-FILHO, A.; HADDAD, A.; JORGE, R.; SCOTT, I.U.; SILVA-CUNHA, A. Pharmacokinetic and toxicity investigations of a new intraocular lens with a dexamethasone drug delivery system (IOL-DDS): a pilot study. Ophthalmologica, v.220, p.338-342, 2006.
41. SMITH, T.J.; PEARSON, P.A.; BLANDFORD, D.L.; BROWN, J.D.; GOINS, K.A.; HOLLINS, E.T.; SCHMEISSER, E.T.; GLAVINOS, P.; BALDWIN, L.B.; ASHTON, P. Intravitreal sustained-release ganciclovir. Arch. Ophthalmol., v.110, p.255-258, 1992.
42. TAN, D.T.H.; CHEE, S.; LIM, L.; LIM, A.S. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of postcataract surgery inflammation. Ophthalmology, v.106, p.223-231, 1999.
43. WADOOD, A.C.; ARMBRECHT, A.M.; ASPINALL, P.A.; DHILLON, B. Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification. J. Cataract Refract. Surg., v.30, p.761-768, 2004.
44. YASUKAWA, T.; KIMURA, H.; TABATA, Y.; MIYAMOTO, H.; HONDA, Y.; OGURA, Y. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Graefes Arch. Clin. Exp. Ophthalmol., v.240, p.672-678, 2002.
45. YASUKAWA, T.; OGURA, Y.; SAKURAI, E.; TABATA, Y.; KIMURA, H. Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Deliv. Rev., v.57, p.2033-2046, 2005.
46. YASUKAWA, T.; OGURA, Y.; TABATA, Y.; KIMURA, H.; WIEDEMANN, P.; HONDA, Y. Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res., v.23, p.253-281, 2004.
47. ZHOU, T.; LEWIS, H.; FOSTER, R.E.; SCHWENDEMAN, S.P. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release, v.55, p.281-295, 1998.